ZIRCONIUM-RADIOLABELED, CYSTEINE ENGINEERED ANTIBODY CONJUGATES

• US 20150017094A1
• Filed: 06/10/2014
• Published: 01/15/2015
• Est. Priority Date: 09/23/2004
• Status: Abandoned Application

• Current Assignee: Genentech, Inc. (Roche Holding AG)
• Original Assignee: Genentech, Inc. (Roche Holding AG)
• Inventors: Gill, Herman, Junutula, Jagath R., Lowman, Henry B., Marik, Jan, Tinianow, Jeff, Williams, Simon
• Application Number:
  US14/300,630
• Publication Number:
  US 20150017094A1
• Time in Patent Office: Days
• US Class Current: 424/1.49
• CPC Class Codes: A01K 2267/0331 Animal model for proliferative diseases
• CPC Class Codes: A61K 51/1027 against receptors, cell-surface antigens or cell-surface determinants
• CPC Class Codes: A61K 51/1051 the tumor cell being from breast, e.g. the antibody being herceptin
• CPC Class Codes: A61K 51/1093 conjugates with carriers being antibodies
• CPC Class Codes: C07C 259/06 having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
• CPC Class Codes: C07C 2601/14 The ring being saturated
• CPC Class Codes: C07C 323/60 with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 16/32 against translation products of oncogenes
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/51 Complete heavy chain or Fd fragment, i.e. VH + CH1
• CPC Class Codes: C07K 2317/52 Constant or Fc region; Isotype
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: C07K 2317/624 Disulfide-stabilized antibody (dsFv)

Abstract

Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab) are conjugated with one or more zirconium complex (Z) labels through a linker (L) to form cysteine engineered zirconium-labeled antibody conjugates having Formula I:

Ab-(L-Z)_p  I

where p is 1 to 4. Imaging methods and diagnostic uses for zirconium-radiolabeled, cysteine engineered antibody conjugate compositions are disclosed.

Claims

1. A zirconium-labelled, cysteine-engineered antibody comprising a cysteine engineered antibody (Ab) conjugated through a free cysteine amino acid to a linker (L) and a zirconium complex (Z), having Formula I:

Ab-(L-Z)_p 

 

I

where p is 1 to 4;

wherein Z comprises zirconium complexed to desferrioxamine B (Df); and

wherein L-Df is selected from;

2. The zirconium-labelled, cysteine-engineered antibody of claim 1 wherein p is 2.

3. The zirconium-labelled, cysteine-engineered antibody of claim 1 wherein the cysteine engineered antibody comprises a sequence in the heavy chain selected from SEQ ID NOS:

11, 12, 13, 15, and 38;

4. The zirconium-labelled, cysteine-engineered antibody of claim 1 wherein the cysteine engineered antibody comprises a sequence in the light chain selected from SEQ ID NOS:

17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 45, and 46;

5. The zirconium-labelled, cysteine-engineered antibody of claim 1 wherein the cysteine engineered antibody is prepared by a process comprising:

(i) mutagenizing a nucleic acid sequence encoding the cysteine engineered antibody;

(ii) expressing the cysteine engineered antibody; and

(iii) isolating and purifying the cysteine engineered antibody.

6. The zirconium-labelled, cysteine-engineered antibody of claim 1 wherein the cysteine engineered antibody is selected from a monoclonal antibody, a bispecific antibody, a chimeric antibody, a human antibody, a humanized antibody, and a Fab fragment.

7. The zirconium-labelled, cysteine-engineered antibody of claim 1 wherein the cysteine engineered antibody is A121C thio-trastuzumab.

8. The zirconium-labelled, cysteine-engineered antibody of claim 1 wherein the cysteine engineered antibody is prepared by a process comprising replacing one or more amino acid residues of a parent antibody with the one or more free cysteine amino acids, where the parent antibody selectively binds to an antigen and the cysteine engineered antibody selectively binds to the same antigen as the parent antibody.

9. The zirconium-labelled, cysteine-engineered antibody of claim 1 wherein the cysteine engineered antibody or the parent antibody binds to one or more of receptors (1)-(51):

(1) BMPR1B (bone morphogenetic protein receptor-type IB);

(2) E16 (LAT1, SLC7A5);

(3) STEAP1 (six transmembrane epithelial antigen of prostate);

(4) 0772P (CA125, MUC16);

(5) MPF (MPF, MSLN, SMR, megakaryocyte potentiating factor, mesothelin);

(6) Napi3b (NAPI-3B, NPTIIb, SLC34A2, solute carrier family 34 (sodium phosphate), member 2, type II sodium-dependent phosphate transporter 3b);

(7) Sema 5b (FLJ10372, KIAA1445, Mm.42015, SEMASB, SEMAG, Semaphorin 5b Hlog, sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5B);

(8) PSCA hlg (2700050C12Rik, C530008O16Rik, RIKEN cDNA 2700050C12, RIKEN cDNA 2700050C12 gene);

(9) ETBR (Endothelin type B receptor);

(10) MSG783 (RNF124, hypothetical protein F1120315);

(11) STEAP2 (HGNC 8639, IPCA-1, PCANAP1, STAMP1, STEAP2, STMP, prostate cancer associated gene 1, prostate cancer associated protein 1, six transmembrane epithelial antigen of prostate 2, six transmembrane prostate protein);

(12) TrpM4 (BR22450, F1120041, TRPM4, TRPM4B, transient receptor potential cation channel, subfamily M, member

     4);

(13) CRIPTO (CR, CR1, CRGF, CRIPTO, TDGF1, teratocarcinoma-derived growth factor);

(14) CD21 (CR2 (Complement receptor

     2) or C3DR (C3d/Epstein Barr virus receptor) or Hs.73792);

(15) CD79b (CD79B, CD79β

, 1 Gb (immunoglobulin-associated beta), B29);

(16) FcRH2 (IFGP4, IRTA4, SPAP1A (SH2 domain containing phosphatase anchor protein 1a), SPAP1B, SPAP1C);

(17) HER2;

(18) NCA;

(19) MDP;

(20) IL20Ra;

(21) Brevican;

(22) EphB2R;

(23) ASLG659;

(24) PSCA;

(25) GEDA;

(26) BAFF-R (B cell-activating factor receptor, BLyS receptor 3, BR3;

(27) CD22 (B-cell receptor CD22-B isoform);

(28) CD79a (CD79A, CD79a, immunoglobulin-associated alpha, a B cell-specific protein that covalently interacts with Ig beta (CD79B) and forms a complex on the surface with IgM molecules, transduces a signal involved in B-cell differentiation);

(29) CXCR5 (Burkitt'"'"'s lymphoma receptor 1, a G protein-coupled receptor that is activated by the CXCL13 chemokine, functions in lymphocyte migration and humoral defense, plays a role in HIV-2 infection and perhaps development of AIDS, lymphoma, myeloma, and leukemia);

(30) HLA-DOB (Beta subunit of MHC class II molecule (Ia antigen) that binds peptides and presents them to CD4+T lymphocytes);

(31) P2X5 (Purinergic receptor P2X ligand-gated ion channel 5, an ion channel gated by extracellular ATP, may be involved in synaptic transmission and neurogenesis, deficiency may contribute to the pathophysiology of idiopathic detrusor instability);

(32) CD72 (B-cell differentiation antigen CD72, Lyb-2);

(33) LY64 (Lymphocyte antigen 64 (RP105), type I membrane protein of the leucine rich repeat (LRR) family, regulates B-cell activation and apoptosis, loss of function is associated with increased disease activity in patients with systemic lupus erythematosis);

(34) FcRH1 (Fc receptor-like protein 1, a putative receptor for the immunoglobulin Fc domain that contains C2 type Ig-like and ITAM domains, may have a role in B-lymphocyte differentiation);

(35) IRTA2 (Immunoglobulin superfamily receptor translocation associated 2, a putative immunoreceptor with possible roles in B cell development and lymphomagenesis;

deregulation of the gene by translocation occurs in some B cell malignancies);

(36) TENB2 (putative transmembrane proteoglycan, related to the EGF/heregulin family of growth factors and follistatin);

(37) PMEL17 (silver homolog;

SILV;

D12S53E;

PMEL17;

(SI);

(SIL);

ME20;

gp100);

(38) TMEFF1 (transmembrane protein with EGF-like and two follistatin-like domains 1;

Tomoregulin-1;

H7365;

C9orf2;

C90RF2;

U19878;

X83961;

(39) GDNF-Ra1 (GDNF family receptor alpha 1;

GFRA1;

GDNFR;

GDNFRA;

RETL1;

TRNR1;

RET 1 L;

GDNFR-alpha1;

GFR-ALPHA-1;

U95 847;

BC014962);

(40) Ly6E (lymphocyte antigen 6 complex, locus E;

Ly67,RIG-E,SCA-2,TSA-1);

(41) TMEM46 (shisa homolog 2 (Xenopus laevis);

SHISA2);

(42) Ly6G6D (lymphocyte antigen 6 complex, locus G6D;

Ly6-D, MEGT1);

(43) LGR5 (leucine-rich repeat-containing G protein-coupled receptor 5;

GPR49, GPR67);

(44) RET (ret proto-oncogene;

MEN2A;

HSCR1;

MEN2B;

MTC1;

(PTC);

CDHF12;

Hs.168114;

RET51;

RET-ELE1);

(45) LY6K (lymphocyte antigen 6 complex, locus K;

LY6K;

HSJ001348;

FLJ35226);

(46) GPR19 (G protein-coupled receptor 19;

Mm.4787);

(47) GPR54 (KISS I receptor;

KISS1R;

GPR54;

HOT7T175;

AXOR12);

(48) ASPHD 1 (aspartate beta-hydroxylase domain containing 1;

LOC253982);

(49) Tyrosinase (TYR;

OCAIA;

OCA1A;

tyrosinase;

SHEP3);

(50) TMEM118 (ring finger protein, transmembrane 2;

RNFT2;

FLJ14627); and

(51) GPR172A (G protein-coupled receptor 172A;

GPCR41;

FLJ11856;

D15Ertd747e).

11. The zirconium-labelled, cysteine-engineered antibody of claim 1 wherein ⁸⁹zirconium is complexed to the structure:

18. A method of imaging comprising:

administering a zirconium-labelled, cysteine-engineered antibody of claim 1 to an animal; and

detecting in vivo the presence of the zirconium-labelled, cysteine-engineered antibody by imaging.

20. The method of claim 18 wherein the zirconium-labelled, cysteine-engineered antibody is a zirconium-labelled, cysteine-engineered antibody of claim 9.

21. The method of claim 18 wherein the animal is a tumor xenograft mouse model.

22. The zirconium-labeled, cysteine engineered antibody of claim 1 wherein the cysteine engineered antibody comprises an A121C mutation or a S400C mutation in the heavy chain.

23. The zirconium-labeled, cysteine engineered antibody of claim 1 wherein the cysteine engineered antibody comprises a V205C mutation in the light chain.

10. (canceled)

12. (canceled)

13. A desferrioxamine-labelled, cysteine-engineered antibody comprising a cysteine engineered antibody (Ab) conjugated through a free cysteine amino acid to a linker (L) and a desferrioxamine moiety (Df), having Formula II:

Ab-(L-Df)_p 

 

II

wherein L-Df is selected from;

14. (canceled)

15. A method of making a desferrioxamine-labelled, cysteine-engineered antibody comprising comprising a cysteine engineered antibody (Ab) conjugated through a free cysteine amino acid to a linker (L) and a desferrioxamine moiety (Df), having Formula II:

Ab-(L-Df)_p 

 

II

wherein L-Df is selected from;

16. A method of making a zirconium-labelled, cysteine-engineered antibody comprising a cysteine engineered antibody (Ab) conjugated through a free cysteine amino acid to a linker (L) and a zirconium complex (Z), having Formula I:

Ab-(L-Z)_p 

 

I

where p is 1 to 4;

the method comprising complexing a zirconium reagent with a desferrioxamine-labelled, cysteine-engineered antibody comprising a cysteine engineered antibody (Ab) conjugated through a free cysteine amino acid to a linker (L) and a desferrioxamine moiety (Df), having Formula II;

Ab-(L-Df)_p 

 

II

wherein L-Df is selected from;

17. The method of claim 16 wherein the zirconium reagent is ⁸⁹zirconium oxalate.

19. (canceled)